The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)
Abstract
BACKGROUND: Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascular/metabolic risk profile than current immunosuppressants. METHODS: Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT and BENEFIT-EXT) of belatacept-based regimens in kidney transplant recipients were assessed at month 12. Each study assessed belatacept in more intensive (MI) and less intensive (LI) regimens versus cyclosporine A (CsA). These secondary endpoints included changes in blood pressure, changes in serum lipids, and the incidence of new-onset diabetes after transplant (NODAT). RESULTS: A total of 1209 patients were randomized and transplanted across the two studies. Mean systolic blood pressure was 6 to 9 mm Hg lower and mean diastolic blood pressure was 3 to 4 mm Hg lower in the MI and LI groups versus CsA (P ≤ 0.002) across both studies at month 12. Non-HDL cholesterol was lower in the belatacept groups versus CsA (P<0.01 MI or LI vs. CsA in each study). Serum triglycerides were lower in the belatacept groups versus CsA (P<0.02 MI or LI vs. CsA in each study). NODAT occurred less often in the belatacept groups versus CsA in a prespecified pooled analysis (P<0.05 MI or LI vs. CsA). CONCLUSIONS: At month 12, belatacept regimens were associated with better cardiovascular and metabolic risk profiles, with lower blood pressure and serum lipids and less NODAT versus CsA. The overall profile of belatacept will continue to be assessed over the 3-year trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An additional consideration is that men with CMD, whether characterized by prediabetes, metabolic syndrome, obesity, or T2D, are at increased risk of hypogonadism and testosterone deficiency.1566–1569”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1569]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Diabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Self-citationVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citationManjunath, G., Tighiouart, H., Ibrahim, H., MacLeod, B., Salem, D. N., Griffith, J. L., Coresh, J., Levey, A. S., & Sarnak, M. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02663-3 · Cited by 920
Research works printed but not linked: 1
- 2003, Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations., Am J Kidney Dis, 41, S11
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Prevention of cardiovascular disease in adult recipients of kidney transplants
Jardine, A. G., Gaston, R. S., Fellstrom, B. C., & Holdaas, H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61334-2 · Cited by 281
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Rostaing, L., Vincenti, F., Grinyó, J., Rice, K. M., Bresnahan, B., Steinberg, S., Gang, S., Gaite, L. E., Moal, M.-C., Mondragón-Ramirez, G. A., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12460 · Cited by 197
Self-citationLong-Term Immunosuppression Management: Opportunities and Uncertainties
Wojciechowski, D., & Wiseman, A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15040920 · Cited by 170
Belatacept for kidney transplant recipients
Masson, P., Henderson, L., Chapman, J. R., Craig, J. C., & Webster, A. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010699.pub2 · Cited by 162
New-Onset Diabetes After Kidney Transplantation—Changes and Challenges
Yates, C. J., Fourlanos, S., Hjelmesaeth, J. S., Colman, P. G., & Cohney, S. J. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03855.x · Cited by 163
The need for minimization strategies: current problems of immunosuppression
Bamoulid, J., Staeck, O., Halleck, F., Khadzhynov, D., Brakemeier, S., Dürr, M., & Budde, K. (2015) · Transplant International · doi:10.1111/tri.12553 · Cited by 153
Renal Transplantation Using Belatacept Without Maintenance Steroids or Calcineurin Inhibitors
Kirk, A. D., Guasch, A., Xu, H., Cheeseman, J. A., Mead, S., Ghali, A., Mehta, A. K., Wu, D., Gebel, H. M., Bray, R. A., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12712 · Cited by 139
Self-citationAdams, A. B., Goldstein, J., Garrett, C., Zhang, R., Patzer, R. E., Newell, K. A., Turgeon, N. A., Chami, A., Guasch, A., Kirk, A. D., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14353 · Cited by 131
Self-citationNew-onset diabetes mellitus after kidney transplantation: Current status and future directions
Palepu, S., & Prasad, G. V. R. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.445 · Cited by 127
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
Kim, S. C., Wakwe, W., Higginbotham, L. B., Mathews, D. V., Breeden, C. P., Stephenson, A., Jenkins, J. B., Strobert, E. A., Price, K., Price, L. A., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14197 · Cited by 100
Self-citationCostimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway
Adams, A. B., Ford, M. L., & Larsen, C. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601135 · Cited by 95
Self-citationEmerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Poirier, N., Dilek, N., Mary, C., Ville, S., Coulon, F., Branchereau, J., Tillou, X., Charpy, V., Pengam, S., Nerrière‐Daguin, V., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12964 · Cited by 91
Long-Term Exposure to Belatacept in Recipients of Extended Criteria Donor Kidneys
Charpentier, B., Pestana, J. O. M., Rial, M. D. C., Rostaing, L. P. E., Grinyo, J. M., Vanrenterghem, Y. F. C., Matas, A. J., Zhang, R., Mühlbacher, F., Pupim, L. B., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12459 · Cited by 87
Self-citationCostimulation Blockade: Current Perspectives and Implications for Therapy
Kinnear, G., Jones, N. D., & Wood, K. J. (2012) · Transplantation · doi:10.1097/tp.0b013e31826d4672 · Cited by 85
A Novel Monoclonal Antibody to CD40 Prolongs Islet Allograft Survival
Lowe, M., Badell, I. R., Thompson, P., Martin, B. P., Leopardi, F., Strobert, E. A., Price, A. A., Abdulkerim, H. S., Wang, R., Iwakoshi, N. N., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04054.x · Cited by 84
Self-citationWissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 89
The safety of calcineurin inhibitors for kidney-transplant patients
Malvezzi, P., & Rostaing, L. P. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1083974 · Cited by 88
Can New-Onset Diabetes After Kidney Transplant Be Prevented?
Chakkera, H. A., Weil, E. J., Pham, P. T., Pomeroy, J. J., & Knowler, W. C. (2013) · Diabetes Care · doi:10.2337/dc12-2067 · Cited by 90
Strategies for an Expanded Use of Kidneys From Elderly Donors
Pérez‐Sáez, M. J., Montero, N., Redondo‐Pachón, D., Crespo, M., & Pascual, J. (2017) · Transplantation · doi:10.1097/tp.0000000000001635 · Cited by 79
Pretransplant Risk Score for New-Onset Diabetes After Kidney Transplantation
Chakkera, H. A., Weil, E. J., Swanson, C. M., Dueck, A. C., Heilman, R. L., Reddy, K. S., Hamawi, K., Khamash, H. A., Moss, A. A., Mulligan, D. C., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0752 · Cited by 72
Complications of Solid Organ Transplantation
Sen, A., Callisen, H. E., Libricz, S. L., & Patel, B. M. (2018) · Critical Care Clinics · doi:10.1016/j.ccc.2018.08.011 · Cited by 81
Misra, D. P., & Shenoy, S. (2016) · Rheumatology International · doi:10.1007/s00296-016-3435-1 · Cited by 71
Belatacept-Resistant Rejection Is Associated With CD28+ Memory CD8 T Cells
Mathews, D. V., Wakwe, W., Kim, S. C., Lowe, M., Breeden, C. P., Roberts, M. E. P., Farris, A. B., Strobert, E. A., Jenkins, J., Larsen, C. P., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14349 · Cited by 71
Self-citationBelatacept: from rational design to clinical application
Wekerle, T., & Grinyo, J. M. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01386.x · Cited by 73
Anwar, I. J., Berman, D. M., DeLaura, I. F., Gao, Q., Willman, M. A., Miller, A., Gill, A., Gill, C., Perrin, S., Ricordi, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6376 · Cited by 69
Tolerogenic therapies in transplantation
Page, E. K., Dar, W. A., & Knechtle, S. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00198 · Cited by 69
T Cell Cosignaling Molecules in Transplantation
Ford, M. L. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.012 · Cited by 70
Rangel, É. B. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.964205 · Cited by 66
New-Onset Diabetes After Kidney Transplantation: Prevalence, Risk Factors, and Management
Sarno, G., Muscogiuri, G., & Rosa, P. D. (2012) · Transplantation · doi:10.1097/tp.0b013e31824db97d · Cited by 64
O’Connell, P. J., Kuypers, D. R. J., Mannon, R. B., Abecassis, M. M., Chadban, S. J., Gill, J. S., Murphy, B. T., Nickerson, P. W., Schold, J. D., Stock, P. G., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001648 · Cited by 60
The past, present, and future of costimulation blockade in organ transplantation
Schroder, P. M., Fitch, Z. W., Schmitz, R., Choi, A. Y., Kwun, J., & Knechtle, S. J. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000656 · Cited by 60
New‐onset diabetes after renal transplantation
Tufton, N., Ahmad, S. N. S., Rolfe, C., Rajkariar, R., Byrne, C., & Chowdhury, T. A. (2014) · Diabetic Medicine · doi:10.1111/dme.12534 · Cited by 64
Novel immunosuppressive agents in kidney transplantation
Hardinger, K. L., & Brennan, D. C. (2013) · World Journal of Transplantation · doi:10.5500/wjt.v3.i4.68 · Cited by 57
Tacrolimus for the prevention and treatment of rejection of solid organ transplants
Scalea, J. R., Levi, S. T., Ally, W. A., & Brayman, K. L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1123093 · Cited by 56
Kean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 52
CD122 signaling in CD8+ memory T cells drives costimulation-independent rejection
Mathews, D. V., Dong, Y., Higginbotham, L. B., Kim, S. C., Breeden, C. P., Stobert, E. A., Jenkins, J., Tso, J. Y., Larsen, C. P., & Adams, A. B. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95914 · Cited by 51
Self-citationDonor and recipient polygenic risk scores influence the risk of post-transplant diabetes
Shaked, A. A., Loza, B., Loon, E. V., Olthoff, K. M., Guan, W., Jacobson, P. A., Zhu, A. X., Fishman, C. E., Gao, H., Oetting, W. S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01758-7 · Cited by 50
Pathogenesis and management of hypertension after kidney transplantation
Chatzikyrkou, C., Menne, J., Gwinner, W., Schmidt, B. M. W., Lehner, F., Blume, C. A., Schwarz, A., Haller, H. G., & Schiffer, M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834bd1e7 · Cited by 50
Badell, I. R., Muraglia, G. M. L., Liu, D., Wagener, M. E., Ding, G., & Ford, M. L. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14400 · Cited by 47
Langsford, D., & Dwyer, K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i10.1132 · Cited by 44
Belatacept in kidney transplantation and its limitations
Noble, J., Jouvé, T., Janbon, B., Rostaing, L. P. E., & Malvezzi, P. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1574570 · Cited by 41
A Pilot Trial Targeting the ICOS–ICOS-L Pathway in Nonhuman Primate Kidney Transplantation
Lo, D. J., Anderson, D. J., Song, M., Leopardi, F., Farris, A. B., Strobert, E. A., Chapin, S. J., Devens, B. H., Karrer, E. E., & Kirk, A. D. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13100 · Cited by 41
Costimulation Blockade in Kidney Transplant Recipients
van der Zwan, M., Hesselink, D. A., van den Hoogen, M. W. F., & Baan, C. C. (2019) · Drugs · doi:10.1007/s40265-019-01226-6 · Cited by 41
Cardiovascular complications after transplantation: Treatment options in solid organ recipients
Gillis, K. A., Patel, R. K., & Jardine, A. G. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.001 · Cited by 39
Adverse Drug Events after Kidney Transplantation
Rostaing, L. P. E., Jouvé, T., Terrec, F., Malvezzi, P., & Noble, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13121706 · Cited by 38
Dobbels, F., Wong, S., Min, Y., Joo, S., & Kalsekar, A. (2014) · Transplantation · doi:10.1097/tp.0000000000000159 · Cited by 38
Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up
Schmitz, R., Fitch, Z. W., Xu, H., Ghali, A., Mehta, A. K., Guasch, A., & Kirk, A. D. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16121 · Cited by 37
New-onset diabetes after kidney transplant in children
Garro, R., Warshaw, B. L., & Felner, E. I. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2830-7 · Cited by 39
Prevention of cardiovascular disease after renal transplantation
Svensson, M. H. S., Jardine, A. G., Fellström, B., & Holdaas, H. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283560a3b · Cited by 37
Immune-based therapies in cardiovascular and metabolic diseases: past, present and future
Murphy, A. J., & Febbraio, M. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00580-5 · Cited by 36
Hansen, C. M., Bachmann, S., Su, M., Budde, K., & Choi, M. (2025) · Acta Physiologica · doi:10.1111/apha.70047 · Cited by 35
Kanbay, M., Çöpür, S., Topçu, A. U., Güldan, M., Özbek, L., Gaipov, A., Ferro, C. J., Cozzolino, M. G., Cherney, D. Z. I., & Tuttle, K. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15575 · Cited by 34
Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future
Kitchens, W. H., Larsen, C. P., & Badell, I. R. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.08.037 · Cited by 33
Self-citationBronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 33
Is Kidney Transplantation a Better State of CKD? Impact on Diagnosis and Management
Parajuli, S., Clark, D. F., & Djamali, A. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.09.006 · Cited by 36
Belatacept: A New Biologic and Its Role in Kidney Transplantation
Su, V., Harrison, J. J., Rogers, C. C., & Ensom, M. H. H. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q537 · Cited by 31
Purnajo, I., Beaumont, J. L., Polinsky, M. S., Alemao, E., & Everly, M. J. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15757 · Cited by 31
Belatacept in kidney transplantation
Wojciechowski, D., & Vincenti, F. G. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32835a4c0d · Cited by 30
Self-citationPrevention and management of new-onset diabetes mellitus in kidney transplantation.
Khong, M. J., & Chong, C. P. (2014) · PubMed · Cited by 29
Validation of a Pretransplant Risk Score for New-Onset Diabetes After Kidney Transplantation
Chakkera, H. A., Chang, Y.-H. H., Ayub, A., Gonwa, T. A., Weil, E. J., & Knowler, W. C. (2013) · Diabetes Care · doi:10.2337/dc13-0428 · Cited by 29
Terrec, F., Jouvé, T., Bennani, H. N., Benhamou, P., Malvezzi, P., Janbon, B., Giovannini, D., Rostaing, L. P. E., & Noble, J. (2019) · Transplantation Direct · doi:10.1097/txd.0000000000000964 · Cited by 31
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
de Graav, G. N., Bergan, S., Baan, C. C., Weimar, W., van Gelder, T., & Hesselink, D. A. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000179 · Cited by 28
Hypertension guidelines: How do they apply to kidney transplant recipients
Aziz, F., Clark, D. F., Garg, N., Mandelbrot, D. A., & Djamali, A. (2018) · Transplantation Reviews · doi:10.1016/j.trre.2018.06.002 · Cited by 28
Ghanta, M., Kozicky, M., & Jim, B. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000044 · Cited by 32
Dyslipidemia in Renal Transplant Recipients
Chmielnicka, K., Heleniak, Z., & Dębska-Ślizień, A. M. (2022) · Transplantology · doi:10.3390/transplantology3020020 · Cited by 28
An update on potentials and promises of T cell co‐signaling molecules in transplantation
Mardomi, A., Mohammadi, N., Khosroshahi, H. H., & Abediankenari, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29369 · Cited by 24
Obesity and Metabolic Syndrome in Kidney Transplantation
LaGuardia, H., & Zhang, R. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0335-6 · Cited by 26
Current status of costimulatory blockade in renal transplantation
Wojciechowski, D., & Vincenti, F. G. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000268 · Cited by 25
Self-citationHernández, D., & Moreso, F. (2013) · PubMed · doi:10.3265/nefrologia.pre2012.nov.11743 · Cited by 24
Melilli, E., Manonelles, A., Montero, N., Grinyo, J. M., Martínez‐Castelao, A., Bestard, O., & Cruzado, J. M. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx120 · Cited by 24
Bertrand, D., Cheddani, L., Étienne, I., François, A., Hanoy, M., Laurent, C., Lebourg, L., Roy, F. L., Lelandais, L., Loron, M.-C., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14427 · Cited by 23
Ippoliti, G., D'Armini, Lucioni, M., Marjieh, & Viganò (2012) · Biologics · doi:10.2147/btt.s27565 · Cited by 23
Kwiatkowska, M., Ołdakowska‐Jedynak, U., Wojtaszek, E., Głogowski, T., & Małyszko, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6660846 · Cited by 22
New Approaches to Cardiovascular Disease and Its Management in Kidney Transplant Recipients
Aziz, F., Jorgenson, M., Garg, N., Parajuli, S., Mohamed, M., Raza, F., Mandelbrot, D. A., Djamali, A., & Dhingra, R. (2021) · Transplantation · doi:10.1097/tp.0000000000003990 · Cited by 23
Immunomodulating options for liver transplant patients
Zarrinpar, A., & Busuttil, R. W. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.47 · Cited by 23
Jayant, K., Reccia, I., Virdis, F., Podda, M., Sharma, A. K., & Halawa, A. M. (2021) · World Journal of Transplantation · doi:10.5500/wjt.v11.i3.70 · Cited by 21
Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation
Arora, S., Tangirala, B., Osadchuk, L., & Sureshkumar, K. K. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.683522 · Cited by 20
Seibert, F. S., Steltzer, J., Melilli, E., Grannas, G., Pagonas, N., Bauer, F., Zidek, W., Grinyo, J. M., & Westhoff, T. H. (2014) · Clinical Transplantation · doi:10.1111/ctr.12413 · Cited by 20
Esposito, P. B., Grosjean, F., Rampino, T., Libetta, C., Gregorini, M., Fasoli, G., Marchi, G., Sileno, G., Montagna, F., & Canton, A. D. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.829470 · Cited by 22
Transfusion-Induced Bone Marrow Transplant Rejection Due to Minor Histocompatibility Antigens
Patel, S. R., & Zimring, J. C. (2013) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2013.08.002 · Cited by 20
Peracha, J., Nath, J., Ready, A. R., Tahir, S., Parekh, K., Hodson, J. A., Ferro, C. J., Borrows, R., & Sharif, A. (2016) · Transplant International · doi:10.1111/tri.12782 · Cited by 20
Iglesias, M., Brennan, D. C., Larsen, C. P., & Raimondi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926648 · Cited by 19
Self-citationBadell, I. R., Kitchens, W. H., Wagener, M. E., Lukacher, A. E., Larsen, C. P., & Ford, M. L. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13399 · Cited by 19
Self-citationParsons, R. F., Larsen, C. P., Pearson, T. C., & Badell, I. R. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-00260-3 · Cited by 19
Self-citationPosttransplant complications: molecular mechanisms and therapeutic interventions
Liu, X., Shen, J., Yan, H., Hu, J., Liao, G., Ding, L., Zhou, S., Zhang, J., Liao, J., Guo, Z., et al. (2024) · MedComm · doi:10.1002/mco2.669 · Cited by 19
Gilson, C. R., Patel, S. R., & Zimring, J. C. (2012) · Transfusion · doi:10.1111/j.1537-2995.2011.03550.x · Cited by 19
Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach
Ducloux, D., & Courivaud, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010116 · Cited by 20
Cellular Immunobiology and Molecular Mechanisms in Alloimmunity—Pathways of Immunosuppression
Schrezenmeier, E. V., Dörner, T., Halleck, F., & Budde, K. (2023) · Transplantation · doi:10.1097/tp.0000000000004646 · Cited by 17
Mulgaonkar, S. P., & Kaufman, D. B. (2014) · Clinical Transplantation · doi:10.1111/ctr.12453 · Cited by 16
pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression
Chevallier, E., Jouvé, T., Rostaing, L. P. E., Malvezzi, P., & Noble, J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851596 · Cited by 16
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future
Noble, J., Léon, J., Bello, A. D., Anglicheau, D., Blancho, G., Ville, S. P., Couzi, L., Grimbert, P., Meur, Y. L., Moulin, B., et al. (2025) · Transplant International · doi:10.3389/ti.2025.14412 · Cited by 15
Belatacept: a new era of immunosuppression?
El‐Charabaty, E., Geara, A. S., Ting, C., El‐Sayegh, S., & Azzi, J. R. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.42 · Cited by 15
Vincenti, F. G., & Wojciechowski (2012) · Biologics · doi:10.2147/btt.s23561 · Cited by 15
Self-citationHennawy, H. M. E., Faifi, A. S. A., Nazer, W. E., Mahedy, A. W., Kamal, A., Faifi, I. S. A., Abdulmalik, H., Safar, O., Zaitoun, M. F., & Fahmy, A. E. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.03.028 · Cited by 14
Bestard, O., Campistol, J. M., Morales, J. M., Sánchez-Fructuoso, A. I., Cabello, M., Cabello, V., Pallardó, L., & Grinyo, J. M. (2012) · PubMed · doi:10.3265/nefrologia.pre2012.jan.11176 · Cited by 13
Self-citationBelatacept utilization recommendations: an expert position
Grinyo, J. M., Budde, K., Citterio, F., & Charpentier, B. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.748747 · Cited by 13
Metadata
- Authors
- Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., & Vincenti, F.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Medical College of Wisconsin (US)
- Hospital Clínic de Barcelona (ES)
- Charité – Universitätsmedizin Berlin (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Emory University (US)
- Instituto Nacional de Cardiología (MX)
- University of California, San Francisco (US)
- Corresponding author
- Vanrenterghem, Yves
- Venue
- Transplantation
- Published
- 2011-05-15
- Volume
- 91
- Issue
- 9
- Pages
- 976-983
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1976465544
- Cited by
- 183
- References
- 67
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 10 · 2020: 5 · 2019: 11 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 24 · 2013: 13 · 2012: 24
- FWCI
- 16.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- belatacept, cyclosporine, kidney transplantation, cardiovascular risk, metabolic risk, blood pressure, serum lipids, non-HDL cholesterol, triglycerides, post-transplant diabetes mellitus, calcineurin inhibitors, immunosuppressive regimens, costimulation blockade
- MeSH terms
- Abatacept, Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Immunosuppressive Agents, Lipids, Male, Middle Aged, Risk Factors, Kidney Transplantation, Cyclosporine, Immunoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.